P53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53

被引:78
|
作者
Chen, LH
Yin, H
Farooqi, B
Sebti, S
Hamilton, AD
Chen, JD
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA
[3] Yale Univ, Dept Chem, New Haven, CT USA
关键词
D O I
10.1158/1535-7163.MCT-04-0342
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression or hyperactivation of MDM2 contributes to functional inactivation of wild-type p53 in nearly 50% of tumors. Inhibition of p53 by MDM2 depends on binding between an NH2-terminal (residues 16 - 28) p53 alpha-helical peptide and a hydrophobic pocket on MDM2, presenting an attractive target for development of inhibitors against tumors expressing wild-type p53. Here we report that novel p53 alpha-helical peptide mimics based on a terphenyl scaffold can inhibit MDM2-p53 binding in vitro and activate p53 in vivo. Several active compounds have been identified that inhibit MDM2-p53 binding in an ELISA assay with IC50 of 10 to 20 mu mol/L and induce p53 accumulation and activation in cell culture at 15 to 40 mu mol/L. These results suggest that p53 alpha-helical mimetics based on the terphenyl scaffold may be developed into potent p53 activators.
引用
收藏
页码:1019 / 1025
页数:7
相关论文
共 50 条
  • [31] IRTKS suppresses p53 activity through promoting MDM2 mediated p53 monoubiquitination
    Zhang, Xin
    Wang, Kesheng
    Sheng, Hailian
    Li, Tingting
    Chen, Gang
    Chen, Fei
    Wang, Qinwan
    Cheng, Zhihong
    Wang, Zhiqin
    Han, Zeguang
    CANCER RESEARCH, 2010, 70
  • [32] p53 mRNA and p53 Protein Structures Have Evolved Independently to Interact with MDM2
    Karakostis, Konstantinos
    Ponnuswamy, Anand
    Fusee, Leila T. S.
    Bailly, Xavier
    Laguerre, Laurent
    Worall, Erin
    Vojtesek, Borek
    Nylander, Karin
    Fahraeus, Robin
    MOLECULAR BIOLOGY AND EVOLUTION, 2016, 33 (05) : 1280 - 1292
  • [33] A second p53 binding site in the central domain of mdm2 is essential for p53 ubiquitination
    Ma, Jianhong
    Martin, John D.
    Zhang, Hong
    Auger, Kurt R.
    Ho, Thau F.
    Kirkpatrick, Robert B.
    Grooms, Michael H.
    Johanson, Kyung O.
    Tummino, Peter J.
    Copeland, Robert A.
    Lai, Zhihong
    BIOCHEMISTRY, 2006, 45 (30) : 9238 - 9245
  • [34] The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
    Huang, Lei
    Yan, Zheng
    Liao, Xiaodong
    Li, Yuan
    Yang, Jie
    Wang, Zhu-Gang
    Zuo, Yong
    Kawai, Hidehiko
    Shadfan, Miriam
    Ganapathy, Suthakar
    Yuan, Zhi-Min
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (29) : 12001 - 12006
  • [35] A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination
    Ma, Jianhong
    Martin, John D.
    Zhang, Hong
    Auger, Kurt A.
    Ho, Than F.
    Kirkpatrick, Robert B.
    Grooras, Michael H.
    Johanson, Kyung
    Tummino, Peter J.
    Copeland, Robert A.
    Lai, Zhihong
    FASEB JOURNAL, 2007, 21 (05): : A273 - A273
  • [36] Nanoparticle mediated inhibition of the MDM2:p53 interaction
    Arvizo, Rochelle R.
    Fischer, Nicholas O.
    Jerry, D. Joseph
    Rotello, Vincent M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233
  • [37] Small molecule inhibitors of p53/MDM2 interaction
    Fotouhi, N
    Graves, B
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) : 159 - 165
  • [38] Targeting the p53–MDM2 interaction to treat cancer
    C Klein
    L T Vassilev
    British Journal of Cancer, 2004, 91 : 1415 - 1419
  • [39] Molecular mechanism of the interaction between MDM2 and p53
    Schon, O
    Friedler, A
    Bycroft, M
    Freund, SMV
    Fersht, AR
    JOURNAL OF MOLECULAR BIOLOGY, 2002, 323 (03) : 491 - 501
  • [40] p53 gene status and expression of p53, MDM2, and p14ARF proteins in ameloblastomas
    Kumamoto, H
    Izutsu, T
    Ohki, K
    Takahashi, N
    Ooya, K
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2004, 33 (05) : 292 - 299